Portal de Periódicos da CAPES

Nebivolol vs Amlodipine as First-line Treatment of Essential Arterial Hypertension in the Elderly

2002; Taylor & Francis; Volume: 11; Issue: 3 Linguagem: Inglês

10.1080/080370502760050421

1651-1999

Alberto Mazza, Blas Gil Extremera, A Maldonato, Torakis Toutouzas, Achille C. Pessina,

Sodium Intake and Health

The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension. One hundred and eighty-four subjects aged S 65 years were screened. After a run-in phase of 4 weeks, only 168 of these were randomized with either nebivolol 2.5- 5 mg daily ( n = 81) or amlodipine 5-10 mg daily ( n = 87) over a period of 12 weeks. The response rate to treatment and the changes of sitting diastolic blood pressure (BP) at week 12 were similar between the two groups. A lower sitting systolic BP (SBP) was detected with amlodipine at week 4 ( p < 0.05) and at week 8 ( p < 0.05). Standing BP showed no changes between the two groups; only SBP was lower with amlodipine at week 8 ( p < 0.05). Heart rate was lower at all treatment visits with nebivolol ( p < 0.001). The incidence of adverse events was no different between the two groups; however the incidence of headache and ankle oedema was significantly higher with amlodipine ( p < 0.05). In elderly subjects with essential hypertension, the antihypertensive efficacy of nebivolol and amlodipine was similar. Both drugs were well tolerated, although amlodipine was accompanied by higher incidence of drug-related adverse events.